These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37006779)

  • 41. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis.
    Liao Y; Wang L; Liu F; Zhou Y; Lin X; Zhao Z; Xu S; Tang D; Jiao Y; Yang L; Yu W; Gao P
    Front Endocrinol (Lausanne); 2023; 14():1078149. PubMed ID: 36761200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. From MAFLD to hepatocellular carcinoma and everything in between.
    Bae SDW; George J; Qiao L
    Chin Med J (Engl); 2022 Feb; 135(5):547-556. PubMed ID: 35191421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
    Ahumada A; Rayón L; Usón C; Bañares R; Alonso Lopez S
    World J Gastroenterol; 2021 Oct; 27(40):6737-6749. PubMed ID: 34790004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathological Features of Hepatocellular Carcinoma with Metabolic Risk Factors.
    Sun L; Zhao H; Ding XY; Yang K; Wang GS; Chen JM; Han XY; Wan G; Zhang L; Zhou XG; Chen XM; Wang P; Xie W
    J Hepatocell Carcinoma; 2023; 10():833-846. PubMed ID: 37304209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infections at the nexus of metabolic-associated fatty liver disease.
    Boeckmans J; Rombaut M; Demuyser T; Declerck B; Piérard D; Rogiers V; De Kock J; Waumans L; Magerman K; Cartuyvels R; Rummens JL; Rodrigues RM; Vanhaecke T
    Arch Toxicol; 2021 Jul; 95(7):2235-2253. PubMed ID: 34027561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C.
    Al-Omary A; Byth K; Weltman M; George J; Eslam M
    J Dig Dis; 2022 Jan; 23(1):33-43. PubMed ID: 34902220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.
    Lodato F; Mazzella G; Festi D; Azzaroli F; Colecchia A; Roda E
    World J Gastroenterol; 2006 Dec; 12(45):7239-49. PubMed ID: 17143937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.
    Desai A; Sandhu S; Lai JP; Sandhu DS
    World J Hepatol; 2019 Jan; 11(1):1-18. PubMed ID: 30705715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
    Nguyen VH; Le MH; Cheung RC; Nguyen MH
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective.
    Fouad Y; Lazarus JV; Negro F; Peck-Radosavljevic M; Sarin SK; Ferenci P; Esmat G; Ghazinian H; Nakajima A; Silva M; Lee S; Colombo M
    Aliment Pharmacol Ther; 2021 May; 53(10):1080-1089. PubMed ID: 33751604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Cholankeril G; El-Serag HB
    Semin Liver Dis; 2023 Feb; 43(1):89-99. PubMed ID: 36216350
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study.
    Attia D; Abdel Alem S; El-Akel W; Abdel-Razek W; Eslam M; Fouad Y; Waked I
    Aliment Pharmacol Ther; 2022 Dec; 56(11-12):1581-1590. PubMed ID: 36168675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem.
    Le Garf S; Nègre V; Anty R; Gual P
    Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study.
    Lin YP; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Tsai MC
    Front Oncol; 2022; 12():816472. PubMed ID: 35186751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced liver fibrosis among hemodialysis patients in a multiethnic urban population in Malaysia.
    Wong WK; Chan WK; Ganapathy SS; Lim SK
    Semin Dial; 2023 Mar; 36(2):107-116. PubMed ID: 35821201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.